Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC STEM CELL THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 ASIA PACIFIC STEM CELL THERAPY MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS FOR THE ASIA PACIFIC STEM CELL THERAPY MARKET
7 ASIA PACIFIC STEM CELL THERAPY MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 THE RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES
8.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT AND AVAILABILITY OF FUNDING FOR STEM CELL RESEARCH
8.1.3 GROWING BIOTECHNOLOGY SECTOR
8.1.4 RISE IN GMP CERTIFICATION APPROVALS FOR CELL THERAPY PRODUCTION FACILITIES
8.1.5 RISE IN CLINICAL TRIALS FOR STEM-CELL-BASED THERAPIES
8.2 RESTRAINTS
8.2.1 THE RISE IN COST OF STEM-CELL-BASED THERAPY RESEARCH
8.2.2 THE RISKS FACED WHILE UNDERGOING STEM CELL THERAPY
8.2.3 ETHICAL CONCERNS RELATED TO STEM CELL THERAPY RESEARCH
8.2.4 AVAILABILITY OF ALTERNATIVES
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
8.3.2 RISE IN HEALTHCARE EXPENDITURE
8.3.3 THE EMERGENCE OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)
8.4 CHALLENGES
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR STEM CELL THERAPY
8.4.2 STRINGENT REGULATIONS
9 ASIA PACIFIC STEM CELL THERAPY MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 BONE MARROW DERIVED MESENCHYMAL STEM CELLS
9.3 PLACENTAL/UMBILICAL STEM CELL
9.4 ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS
9.5 OTHERS
10 ASIA PACIFIC STEM CELL THERAPY MARKET, BY TYPE
10.1 OVERVIEW
10.2 ALLOGENEIC STEM CELL THERAPY
10.2.1 MUSCULOSKELETAL DISORDERS
10.2.2 WOUNDS AND INJURIES
10.2.3 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
10.2.4 SURGERIES
10.2.5 GASTROINTESTINAL DISEASES
10.2.6 OTHER APPLICATION
10.3 AUTOLOGOUS STEM CELL THERAPY
10.3.1 CARDIOVASCULAR DISEASES
10.3.2 GASTROINTESTINAL DISEASES
10.3.3 OTHER APPLICATION
11 ASIA PACIFIC STEM CELL THERAPY MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 MUSCULOSKELETAL DISORDERS
11.3 WOUNDS AND INJURIES
11.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
11.5 SURGERIES
11.6 GASTROINTESTINAL DISEASES
11.7 CARDIOVASCULAR DISEASES
11.8 OTHER APPLICATION
12 ASIA PACIFIC STEM CELL THERAPY MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL AND SURGICAL CENTERS
12.3 THERAPEUTIC COMPANIES
12.4 SERVICES COMPANIES
12.5 OTHERS
13 ASIA PACIFIC STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 THIRD PARTY DISTRIBUTORS
14 ASIA PACIFIC STEM CELL THERAPY MARKET, BY REGION
14.1 ASIA-PACIFIC
14.1.1 SOUTH KOREA
14.1.2 JAPAN
14.1.3 INDIA
15 ASIA PACIFIC STEM CELL THERAPY MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 OSIRIS THERAPEUTICS, INC. (A SUBSIDIARY OF SMITH+NEPHEW) (2021)
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 JCR PHARMACEUTICALS CO., LTD ( (2021)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 ORTHOFIX MEDICAL INC. (2021)
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 MEDIPOST (2021)
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 CORESTEM, INC. (2021)
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 PHARMICELL CO., LTD. (2021)
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 ANTEROGEN.CO., LTD (2021)
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENTS
17.9 ATHERSYS, INC.(2021)
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 BRAINSTORM CELL LIMITED (2021)
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENTS
17.11 BIORESTORATIVE THERAPIES, INC. (2021)
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 HOLOSTEM TERAPIE AVANZATE S.R.L. (2021)
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENTS
17.13 INTERNATIONAL STEMCELL CORPORATION (2021)
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 MESOBLAST LTD (2021)
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 PLURISTEM INC.(2021)
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 STEMPEUTICS RESEARCH PVT LTD
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 U.S. STEM CELL, INC. (2021)
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 ASIA PACIFIC STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 2 ASIA PACIFIC BONE MARROW DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC PLACENTAL/UMBILICAL STEM CELL IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC MUSCULOSKELETAL DISORDERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC WOUNDS AND INJURIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC SURGERIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC GASTROINTESTINAL DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC CARDIOVASCULAR DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC OTHER APPLICATION IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC HOSPITAL AND SURGICAL CENTERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC THERAPEUTIC COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC SERVICES COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC DIRECT TENDER IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC THIRD PARTY DISTRIBUTORS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 SIA-PACIFIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 28 ASIA-PACIFIC STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 29 ASIA-PACIFIC STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 ASIA-PACIFIC ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 31 ASIA-PACIFIC AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 32 ASIA-PACIFIC STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 33 ASIA-PACIFIC STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 ASIA-PACIFIC STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 SOUTH KOREA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 36 SOUTH KOREA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 SOUTH KOREA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 38 SOUTH KOREA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 39 SOUTH KOREA STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 40 SOUTH KOREA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 SOUTH KOREA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 JAPAN STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 43 JAPAN STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 JAPAN ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 45 JAPAN AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 46 JAPAN STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 47 JAPAN STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 48 JAPAN STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 49 INDIA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 50 INDIA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 INDIA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 52 INDIA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 53 INDIA STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 54 INDIA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 55 INDIA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 ASIA PACIFIC STEM CELL THERAPY MARKET : SEGMENTATION
FIGURE 2 ASIA PACIFIC STEM CELL THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC STEM CELL THERAPY MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC STEM CELL THERAPY MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC STEM CELL THERAPY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC STEM CELL THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC STEM CELL THERAPY MARKET: DBMR POSITION GRID
FIGURE 8 ASIA PACIFIC STEM CELL THERAPY MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 ASIA PACIFIC STEM CELL THERAPY MARKET: END USER COVERAGE GRID
FIGURE 10 ASIA PACIFIC STEM CELL THERAPY MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE ASIA PACIFIC STEM CELL THERAPY MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASED INCIDENCE OF CHRONIC DISEASES, RISE IN CLINICAL TRIALS, GMP CERTIFICATION AND PRODUCT APPPROVALS IS EXPECTED TO DRIVE THE ASIA PACIFIC STEM CELL THERAPY MARKET FROM 2022 TO 2029
FIGURE 13 PRODUCT TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE ASIA PACIFIC STEM CELL THERAPY MARKET FROM 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC STEM CELL THERAPY MARKET
FIGURE 15 NUMBER AND AGES OF PEOPLE 65 OR OLDER WITH ALZHEIMER'S DEMENTIA IN 2022
FIGURE 16 INCIDENCE OF VARIOUS TYPES OF CANCER IN 2020
FIGURE 17 ASIA PACIFIC STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2021
FIGURE 18 ASIA PACIFIC STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)
FIGURE 19 ASIA PACIFIC STEM CELL THERAPY MARKET: BY PRODUCT TYPE, CAGR (2022-2029)
FIGURE 20 ASIA PACIFIC STEM CELL THERAPY MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 ASIA PACIFIC STEM CELL THERAPY MARKET: BY TYPE, 2021
FIGURE 22 ASIA PACIFIC STEM CELL THERAPY MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 23 ASIA PACIFIC STEM CELL THERAPY MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 24 ASIA PACIFIC STEM CELL THERAPY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 ASIA PACIFIC STEM CELL THERAPY MARKET: BY APPLICATION, 2021
FIGURE 26 ASIA PACIFIC STEM CELL THERAPY MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 27 ASIA PACIFIC STEM CELL THERAPY MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 28 ASIA PACIFIC STEM CELL THERAPY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 29 ASIA PACIFIC STEM CELL THERAPY MARKET: BY END USER, 2021
FIGURE 30 ASIA PACIFIC STEM CELL THERAPY MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 31 ASIA PACIFIC STEM CELL THERAPY MARKET: BY END USER, CAGR (2022-2029)
FIGURE 32 ASIA PACIFIC STEM CELL THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 33 ASIA PACIFIC STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 34 ASIA PACIFIC STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 35 ASIA PACIFIC STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 36 ASIA PACIFIC STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 ASIA-PACIFIC STEM CELL THERAPY MARKET: SNAPSHOT (2021)
FIGURE 38 ASIA-PACIFIC STEM CELL THERAPY MARKET: BY COUNTRY (2021)
FIGURE 39 ASIA-PACIFIC STEM CELL THERAPY MARKET: BY COUNTRY (2022 & 2029)
FIGURE 40 ASIA-PACIFIC STEM CELL THERAPY MARKET: BY COUNTRY (2021 & 2029)
FIGURE 41 ASIA-PACIFIC STEM CELL THERAPY MARKET: BY PRODUCT TYPE (2022 & 2029)
FIGURE 42 ASIA PACIFIC STEM CELL THERAPY MARKET: COMPANY SHARE 2021 (%)
